All In Biotech

Drug Trial Radar · NCT04573192

A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression

A Study to Evaluate the Safety and Efficacy of the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression

Last checked: Nov 19, 2026Latest source record: Apr 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 142 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

142

Planned (sponsor's estimate)

Start

Feb 19, 2021

Primary completion

Mar 2025

Study completion Dec 2025

Sponsor

Lead sponsor
Philogen S.p.A.Industry
Sponsor type
Industry
First posted
Oct 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Glioblastomas are the most common and most aggressive primary brain tumors in adults. The prognosis is poor despite multimodal therapy with surgery, radiotherapy and chemotherapy. Therefore, novel treatments are urgently needed. L19TNF is a fully human fusion protein consisting of human tumor necrosis factor (TNF)-α fused to the L19 antibody in scFv format, specific to the extra-domain B of fibronectin. TNF not only induces apoptosis or necrosis in certain target cells, but also exerts inflammation and immunity. L19TNF selectively delivers TNF to the tumor site to spare normal tissues from undesired toxicity. Preclinical experiments with L19TNF have demonstrated tumor growth retardation in various mouse tumor models including models of glioma.

Conditions

  • Glioblastoma

Interventions

  • L19TNFDrug

    Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine

  • LomustineDrug

    Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. For Phase 1: DLTTime frame: For Cohort 1 to Cohort 3 from Day 1 to Day 42 after the first administration of lomustine and study drug (Cycle 1)
  2. For Phase 2: Overall SurvivalTime frame: From beginning of treatment to 12 months

Locations

15 sites in 4 countries. Site status is shown where the registry gives one.

  • Hôpital Neurologique Pierre Wertheimer

    Bron, France · Not yet recruiting

  • Hôpital Saint Louis

    Paris, France · Not yet recruiting

  • Sorbonne University, AP-HP, Paris brain institute

    Paris, France · Not yet recruiting

  • University Hospital Bonn

    Bonn, Germany · Recruiting

  • University Hospital Köln

    Cologne, Germany · Not yet recruiting

  • Klinikum rechts der Isar

    München, Germany · Recruiting

  • Universitatsklinikum Tubingen

    Tübingen, Germany · Recruiting

  • Azienda USL di Bologna IRCCS delle Scienze Neurologiche di Bologna

    Bologna, Italy · Recruiting

  • Fondazione IRCCS Istituto Neurologico Carlo Besta

    Milan, Italy · Recruiting

  • Istituto Oncologico Veneto IRCCS

    Padova, Italy · Recruiting

  • Azienda Ospedaliero-Universitaria Senese Policlinico Le Scotte

    Siena, Italy · Not yet recruiting

  • AOU Città della Salute e della Scienza di Torino

    Torino, Italy · Not yet recruiting

  • Inselspital Universitätsklinik für Medizinische Onkologie Bern

    Bern, Switzerland · Recruiting

  • Centre Hospitalier Universitaire Vaudois (CHUV)

    Lausanne, Switzerland · Recruiting

  • Universitatspital Zurich - Klinik fur Neurologie & Hirntumorzentrum

    Zurich, Switzerland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.